Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David C. Hunden is active.

Publication


Featured researches published by David C. Hunden.


Tetrahedron | 1989

Molecular modeling of γ-lactam analogues of β-lactam antibacterial agents: synthesis and biological evaluation of selected penem and carbapenem analoques

Norris E. Allen; Donald B. Boyd; Jack B. Campbell; Jack B. Deeter; Thomas K. Elzey; Bennie Joe Foster; Lowell D. Hatfield; Joseph N. Hobbs; William Joseph Hornback; David C. Hunden; Noel D. Jones; Michael Dean Kinnick; John M. Morin; John E. Munroe; John K. Swartzendruber; David G. Vogt

Abstract Computational chemistry made possible the prediction of the three-dimensional structures of γ-lactam analogues of penems and carbapenems before the analogues were made. Molecular superpositioning showed that these novel structures with a 7β-acylamino side-chain present the pharmacophoric groups in close spatial similarity to the groups in biologically active cephalosporin and penicillin antibiotics. This suggests that 8-oxo-7-acylamino-1-azabicyclo[3.3.0]-oct-2-ene-2-carboxylates and the 4-thia-analogues can be accommodated in the same active sites of essential bacterial penicillin-binding proteins where cephalosporins and penicillins are recognized. The syntheses of these compounds are reported. The γ-lactams exhibit low, but detectable levels of antibacterial activity and suggest promise that substantial activity can be achieved with other γ-lactams.


Bioorganic & Medicinal Chemistry Letters | 1996

Synthesis and structure-activity relationships of benzophenones as inhibitors of cathepsin D

Celia A. Whitesitt; Richard Lee Simon; Jon K. Reel; Sandra Kay Sigmund; Michael Leroy Phillips; J. Kevin Shadle; Lawrence Joseph Heinz; Gary A. Koppel; David C. Hunden; Sherryl Lynn Lifer; Dennis R. Berry; Judy Ray; Sheila P. Little; Xiadong Liu; Winston S. Marshall; Jill Ann Panetta

Abstract Non peptide inhibitors of cathepsin D, an aspartyl protease that has been implicated in many disease states including Alzheimers disease, were prepared and evaluated. The most potent inhibitor of cathepsin D in this series was found to be (Z)-5-[[4-(4-benzoyl-3-hydroxy-2-propylphenoxy) methylphenyl]methylene]-2-thioxo-4-thiazolidinone ( 3f , IC 50 = 210 nM).


Tetrahedron | 1999

Rapid parallel synthesis applied to the optimization of a series of potent nonpeptide neuropeptide Y-1 receptor antagonists

Miles Goodman Siegel; Michael O. Chaney; Robert F. Bruns; Michael P. Clay; Douglas A. Schober; Anne M. Van Abbema; Douglas W. Johnson; Buddy E. Cantrell; Patric James Hahn; David C. Hunden; Donald R. Gehlert; Hamideh Zarrinmayeh; Paul L. Ornstein; Dennis M. Zimmerman; Gary A. Koppel

Abstract This study describes the integrated application of parallel synthesis and computational chemistry to the design of potent nonpeptide antagonists for the neuropeptide Y-1 (NPY1) receptor. A lead molecule was modeled in the active site of the NPY1 receptor, and a potentially fruitful region for analog construction was identified. Synthesis of suitable scaffolds followed by solution phase generation of a small library of analogs produced a compound with 5-fold improvement in binding over the already potent lead. This new compound was shown to be an unanticipated side product of the parallel synthesis reaction.


Chemistry & Biology | 1995

Use of peptide combinatorial libraries in drug design: the identification of a potent serotonin reuptake inhibitor derived from a tripeptide cassette library

Gary A. Koppel; Carmen Dodds; Brenda Houchins; David C. Hunden; Douglas W. Johnson; Rebecca A. Owens; Michael O. Chaney; Theodore Usdin; Beth J. Hoffman; Michael J. Brownstein

BACKGROUND Medicinal chemistry traditionally requires the identification of biologically active molecules by synthesizing and screening each purified substrate. Further progress in drug discovery then requires definition of the structure-activity relationship of the lead compound. More recently, combinatorial chemistry has emerged as a way to examine structure-activity relationships by screening a large mixture of compounds synthesized in a predictably random manner, without the labor-intensive costs of molecular isolation and purification. We set out to use this approach to examine the structural requirements for peptide binding to serotonin and dopamine transporters. RESULTS We screened a tripeptide cassette library for serotonin and dopamine reuptake inhibition using cloned transporter assay systems. The method has afforded a number of tripeptide pharmacophores with inhibitory IC50 values ranging from 10 microM to < 1 microM in the dopamine and serotonin reuptake systems. The conformation of one of these tripeptides, N-acetyl-D-Trp-L-Phe-D-Lys-CONH2 (which inhibits serotonin uptake with an IC50 of 10 microM) was compared to that of the serotonin uptake inhibitor s-fluoxetine, and was shown to be more similar in conformation to fluoxetine than was an analogous tripeptide containing L-Lys (IC50 > 50 microM). CONCLUSIONS We have identified five tripeptides with inhibitory IC50 values of < 10 microM in the serotonin reuptake system. One tripeptide was predicted to have pharmacophore features similar to that of fluoxetine, a selective and potent non-peptide serotonin reuptake inhibitor. Our results suggest that tripeptides derived from combinatorial libraries will help to define the important structural elements of pharmacophores.


Journal of Pharmacology and Experimental Therapeutics | 1998

LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation

Christian C. Felder; Kelly E. Joyce; Eileen M. Briley; Michelle Glass; Ken Mackie; Kennan Joseph Fahey; George Joseph Cullinan; David C. Hunden; Douglas W. Johnson; Michael O. Chaney; Gary A. Koppel; Michael J. Brownstein


Archive | 1993

Compounds useful as hypoglycemic agents and for treating Alzheimer's disease

Juliana Maude Bue-Valleskey; David C. Hunden; Charles David Jones; Jill Ann Panetta; Walter Norman Shaw


Bioorganic & Medicinal Chemistry | 2007

Azetidinones as Vasopressin V1a Antagonists

Christophe Guillon; Gary A. Koppel; Michael J. Brownstein; Michael O. Chaney; Craig F. Ferris; Shi-fang Lu; Karine Fabio; Marvin J. Miller; Ned D. Heindel; David C. Hunden; Robin D. G. Cooper; Stephen W. Kaldor; Jeffrey J. Skelton; Bruce A. Dressman; Michael P. Clay; Mitchell I. Steinberg; Robert F. Bruns; Neal G. Simon


Journal of Medicinal Chemistry | 1985

Orally absorbable cephalosporin antibiotics. 2. Structure-activity studies of bicyclic glycine derivatives of 7-aminodeacetoxycephalosporanic acid.

Stjepan Kukolja; Susan Elizabeth Draheim; Bernard J. Graves; David C. Hunden; Janice L. Pfeil; Robin D. G. Cooper; John L. Ott; F. T. Counter


Archive | 2010

Serotonin and norepinephrine uptake inhibitors

Bennie Joe Foster; David C. Hunden; Edward Ralph Lavagnino


Archive | 1997

Non-peptidyl vasopressin V1a antagonists

Robert F. Bruns; Robin D. G. Cooper; Bruce A. Dressman; David C. Hunden; Stephen W. Kaldor; Gary A. Koppel; John Robert Rizzo; Jeffrey J. Skelton; Mitchell I. Steinberg

Collaboration


Dive into the David C. Hunden's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge